European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: Summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN

Transplant Infectious Disease

Volumn 15, Issue 3, 2013, Pages 219-232

  Engelhard, D ^a,b   Mohty, B ^c   De la Camara, R ^d   Cordonnier, C ^e   Ljungman, P ^f  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MONASH UNIVERSITY   (Australia)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HENRI MONDOR HOSPITAL   (France)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ECIL 4; Guidelines; Hematopoietic stem cell transplantation; HSCT; Influenza; Leukemia; Recommendations; The European Conference on Infections in Leukemia

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR; PREDNISONE; ZANAMIVIR;

ANTIVIRAL THERAPY; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; EVIDENCE BASED PRACTICE; FATALITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; JOINT VENTURE; LEUKEMIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEASONAL INFLUENZA; SENSITIVITY AND SPECIFICITY; STEROID THERAPY; TREATMENT DURATION; VIRUS RESISTANCE; VIRUS SHEDDING;

ACETAMIDES; ANTIVIRAL AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFLUENZA, HUMAN; LEUKEMIA; OSELTAMIVIR; PRACTICE GUIDELINES AS TOPIC; ZANAMIVIR;

EID: 84878635730     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12054     Document Type: Review

References (94)

1. Ljungman P, de la Camara R, Perez-Bercoff L, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica 2011; 96 (8): 1231-1235.
2. Cordonnier C, Calandra T. The first European Conference on Infections in Leukaemia: why and how? Eur J Cancer Suppl 2007; 5 (2): 2-4.
3. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52 (4): e56-e93.
4. Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 1995; 3 (3): 198-202.
5. Weinstock DM, Eagan J, Malak SA, et al. Control of influenza A on a bone marrow transplant unit. Infect Control Hosp Epidemiol 2000; 21 (11): 730-732.
6. Lalayanni C, Sirigou A, Iskas M, Smias C, Sakellari I, Anagnostopoulos A. Outbreak of novel influenza A (H1N1) in an adult haematology department and haematopoietic cell transplantation unit: clinical presentation and outcome. J Infect 2010; 61 (3): 270-272.
7. Cunha BA, Thekkel V, Krilov L. Nosocomial swine influenza (H1N1) pneumonia: lessons learned from an illustrative case. J Hosp Infect 2010; 74 (3): 278-281.
8. Espinosa-Aguilar L, Green JS, Forrest GN, et al. Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers' experiences. Biol Blood Marrow Transplant 2011; 17 (4): 566-573.
9. Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10 (8): 521-526.
10. Sivadon-Tardy V, Orlikowski D, Porcher R, et al. Guillain-Barre syndrome and influenza virus infection. Clin Infect Dis 2009; 48 (1): 48-56.
11. Potter MN, Foot AB, Oakhill A. Influenza A and the virus associated haemophagocytic syndrome: cluster of three cases in children with acute leukaemia. J Clinical Pathol 1991; 44 (4): 297-299.
12. Beutel G, Wiesner O, Eder M, et al. Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care 2011; 15 (2): R80.
13. Nozoe M, Iino T, Nagafuji K, et al. Influenza-induced rhabdomyolysis after autologous peripheral blood stem cell transplantation for malignant lymphoma. Intern Med 2003; 42 (11): 1127-1130.
14. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60 (1): 1-24.
15. Kuypers J, Campbell AP, Cent A, Corey L, Boeckh M. Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients. Transpl Infect Dis 2009; 11 (4): 298-303.
16. Campbell AP, Chien JW, Kuypers J, et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J Infect Dis 2010; 201 (9): 1404-1413.
17. Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med 2012; 156 (7): 500-511.
18. Yousuf HM, Englund J, Couch R, et al. Influenza among hospitalized adults with leukemia. Clin Infect Dis 1997; 24 (6): 1095-1099.
19. Wei JY, Chen FF, Jin J, et al. Novel influenza A (H1N1) in patients with hematologic disease. Leukemia Lymphoma 2010; 51 (11): 2079-2083.
20. Whimbey E, Elting LS, Couch RB, et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994; 13 (4): 437-440.
21. Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28 (5): 479-484.
22. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39 (9): 1300-1306.
23. Caselli D, Carraro F, Castagnola E, et al. Morbidity of pandemic H1N1 influenza in children with cancer. Pediatr Blood Cancer 2010; 55 (2): 226-228.
24. Launes C, Rives S, Catala A, et al. Pandemic influenza A (2009 H1N1) in children with acute lymphoblastic leukaemia. Br J Haematol 2010; 149 (6): 874-878.
25. Karapinar DY, Ay Y, Karzaoglu Z, et al. Experience of pandemic influenza with H1N1 in children with leukemia. Pediatr Hematol Oncol 2011; 28 (1): 31-36.
26. Zeller B, Hellebostad M. H1N1 infection in children with haematological and oncological diseases in Norway. Acta Paediatr 2011; 100 (8): 1134-1137.
27. Sule U, Muge G, Selin AE, Murat T, Mualla C, Fatma G. Mild to fatal course of pandemic influenza H1N1 in children with acute leukaemia. Br J Haematol 2011; 152 (4): 492-493.
28. Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997; 102 (3A): 27-30.
29. Raboni SM, Nogueira MB, Tsuchiya LR, et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 2003; 76 (1): 142-146.
30. Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant 2003; 31 (8): 695-700.
31. Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine 2006; 85 (5): 278-287.
32. Koskenvuo M, Mottonen M, Rahiala J, et al. Respiratory viral infections in children with leukemia. Pediatr Infect Dis J 2008; 27 (11): 974-980.
33. Aschan J, Ringden O, Ljungman P, Andersson J, Lewensohn-Fuchs I, Forsgren M. Influenza B in transplant patients. Scand J Infect Dis 1989; 21 (3): 349-350.
34. Ljungman P, Andersson J, Aschan J, et al. Influenza A in immunocompromised patients. Clin Infect Dis 1993; 17 (2): 244-247.
35. Mellouli F, Ouederni M, Dhouib N, Hajkacem MA, Slim A, Bejaoui M. Successful treatment of influenza A virus by oseltamivir in bone marrow transplant recipients. Pediatr Transplant 2010; 14 (2): 178-181.
36. Redelman-Sidi G, Sepkowitz KA, Huang CK, et al. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J Infect 2010; 60 (4): 257-263.
37. Tekgunduz E, Yuksel MK, Erbay C, et al. Pandemic 2009 H1N1 influenza in patients with hematopoietic stem cell transplantation and hematologic malignancy: single center experience. Oncology 2010; 79 (5-6): 409-414.
38. Tramontana AR, George B, Hurt AC, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010; 16 (7): 1068-1075.
39. Couturier BA, Bender JM, Schwarz MA, Pavia AT, Hanson KE, She RC. Oseltamivir-resistant influenza A 2009 H1N1 virus in immunocompromised patients. Influenza Other Respir Viruses 2010; 4 (4): 199-204.
40. Rihani R, Hayajneh W, Sultan I, et al. Infections with the 2009 H1N1 influenza virus among hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant 2011; 46 (11): 1430-1436.
41. Garland P, de Lavallade H, Sekine T, et al. Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation. Biol Blood Marrow Transplant 2011; 17 (5): 632-639.
42. Cost C, Brock E, Adams-Huet B, Siegel JD, Ardura MI. 2009 pandemic influenza A (H1N1) virus infection in pediatric oncology and hematopoietic stem cell transplantation patients. Pediatr Blood Cancer 2011; 56 (1): 127-133.
43. Choi SM, Boudreault AA, Xie H, Englund JA, Corey L, Boeckh M. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood 2011; 117 (19): 5050-5056.
44. Schiffer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica 2009; 94 (8): 1101-1108.
45. Boudreault AA, Xie H, Leisenring W, Englund J, Corey L, Boeckh M. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. Biol Blood Marrow Transplant 2011; 17 (7): 979-986.
46. Martin-Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med 2011; 37 (2): 272-283.
47. Kim SH, Hong SB, Yun SC, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011; 183 (9): 1207-1214.
48. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11 (2): 100-105.
49. Cohen-Daniel L, Zakay-Rones Z, Resnick IB, et al. Emergence of oseltamivir-resistant influenza A/H3N2 virus with altered hemagglutination pattern in a hematopoietic stem cell transplant recipient. J Clinl Virol 2009; 44 (2): 138-140.
50. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010; 363 (14): 1381-1382.
51. Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 2007; 44 (7): 964-967.
52. Maeda M, Fukunaga Y, Asano T, Migita M, Ueda T, Hayakawa J. Zanamivir is an effective treatment for influenza in children undergoing therapy for acute lymphoblastic leukemia. Scand J Infect Dis 2002; 34 (8): 632-633.
53. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010; 362 (1): 88-89.
54. Renaud C, Pergam SA, Polyak C, et al. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis 2010; 12 (6): 513-517.
55. Campbell AP, Jacob ST, Kuypers J, et al. Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. Ann Intern Med 2010; 152 (9): 619-620.
56. Yu Y, Garg S, Yu PA, et al. Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010. Clin Infect Dis 2012; 55 (1): 8-15.
57. Fraaij PL, van der Vries E, Beersma MF, et al. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J Infect Dis 2011; 204 (5): 777-782.
58. Kobayashi S, Kimura F, Kobayashi A, Sato K, Motoyoshi K. Influenza virus reactivation after remission with oseltamivir treatment in a patient undergoing nonmyeloablative bone marrow transplantation. J Infection Chemother 2008; 14 (4): 308-310.
59. Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood 2010; 115 (7): 1331-1342.
60. Schafer AI, Churchill WH, Ames P, Weinstein L. The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine. Cancer 1979; 43 (1): 25-30.
61. Steinherz PG, Brown AE, Gross PA, et al. Influenza immunization of children with neoplastic diseases. Cancer 1980; 45 (4): 750-756.
62. Lange B, Shapiro SA, Waldman MT, Proctor E, Arbeter A. Antibody responses to influenza immunization of children with acute lymphoblastic leukemia. J Infect Dis 1979; 140 (3): 402-406.
63. Brydak LB, Rokicka-Milewska R, Machala M, Jackowska T, Sikorska-Fic B. Immunogenicity of subunit trivalent influenza vaccine in children with acute lymphoblastic leukemia. Pediatr Infect Dis J 1998; 17 (2): 125-129.
64. Chisholm JC, Devine T, Charlett A, Pinkerton CR, Zambon M. Response to influenza immunisation during treatment for cancer. Arch Dis Child 2001; 84 (6): 496-500.
65. Hsieh YC, Lu MY, Kao CL, et al. Response to influenza vaccine in children with leukemia undergoing chemotherapy. J Formos Med Assoc 2002; 101 (10): 700-704.
66. Porter CC, Edwards KM, Zhu Y, Frangoul H. Immune responses to influenza immunization in children receiving maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2004; 42 (1): 36-40.
67. Reilly A, Kersun LS, McDonald K, Weinberg A, Jawad AF, Sullivan KE. The efficacy of influenza vaccination in a pediatric oncology population. J Pediatr Hematol Oncol 2010; 32 (5): e177-e181.
68. Shahgholi E, Ehsani MA, Salamati P, Maysamie A, Sotoudeh K, Mokhtariazad T. Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy. Pediatr Blood Cancer 2010; 54 (5): 716-720.
69. Cheuk DK, Chiang AK, Lee TL, Chan GC, Ha SY. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev 2011; March 16 (3): CD006505.
70. Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993; 11 (1): 1-5.
71. Pauksen K, Linde A, Hammarstrom V, et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis 2000; 30 (2): 342-348.
72. Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant 2005; 36 (10): 897-900.
73. Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008; 86 (2): 257-263.
74. de Lavallade H, Garland P, Sekine T, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2011; 96 (2): 307-314.
75. Bate J, Yung CF, Hoschler K, et al. Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. Clin Infect Dis 2010; 51 (12): e95-e104.
76. Roll D, Ammer J, Holler B, et al. Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Infection 2012; 40 (2): 153-161.
77. Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011; 118 (26): 6769-6771.
78. Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17 (3): 434-438.
79. Engelhard D, Zakay-Rones Z, Shapira MY, et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine 2011; 29 (9): 1777-1782.
80. Mohty B, Bel M, Vukicevic M, et al. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2011; 96 (6): 896-904.
81. Gueller S, Allwinn R, Mousset S, et al. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17 (10): 1546-1550.
82. Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 2007; 45 (2): 187-193.
83. Ison MG, Szakaly P, Shapira MY, Krivan G, Nist A, Dutkowski R. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients. Antivir Ther 2012; 17 (6): 955-964.
84. Ferguson PE, Jordens CF, Gilroy NM. Patient and family education in HSCT: improving awareness of respiratory virus infection and influenza vaccination. A descriptive study and brief intervention. Bone Marrow Transplant 2010; 45 (4): 656-661.
85. Influenza case definitions. European Centre for Disease Prevention and Control. Available from: http://ecdc.europa.eu/en/activities/surveillance/EISN/surveillance/Pages/influenza_case_definitions.aspx (Accessed 1 July, 2012)
86. Kim C, Ahmed JA, Eidex RB, et al. Comparison of nasopharyngeal and oropharyngeal swabs for the diagnosis of eight respiratory viruses by real-time reverse transcription-PCR assays. PLoS One 2011; 6 (6): e21610.
87. Hammitt LL, Kazungu S, Welch S, et al. Added value of an oropharyngeal swab in detection of viruses in children hospitalized with lower respiratory tract infection. J Clin Microbiol 2011; 49 (6): 2318-2320.
88. Ditschkowski M, Elmaagacli AH, Beelen DW. H1N1 in allogeneic stem cell recipients: courses of infection and influence of vaccination on graft-versus-host-disease (GVHD). Ann Hematol 2011; 90 (1): 117-118.
89. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010; 7 (11): e1000362.
90. Perelson AS, Rong L, Hayden FG. Combination antiviral therapy for influenza: predictions from modeling of human infections. J Infect Dis 2012; 205 (11): 1642-1645.
91. Hoopes JD, Driebe EM, Kelley E, et al. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS One 2011; 6 (12): e29778.
92. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010; 5 (2): e9332.
93. Nguyen JT, Smee DF, Barnard DL, et al. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One 2012; 7 (1): e31006.
94. Kim WY, Young Suh G, Huh JW, et al.; Korean Society of Critical Care Medicine H1N1 Collaborative. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 2011; 55 (12): 5703-5709.